Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (53 quarters reported)
$254M in Q2 2013 → $2.2B now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Aurinia Pharmaceuticals Inc | 10.1% | Added 6.7% | 13,044,106 | $221M |
| Spyre Therapeutics Inc | 7.6% | Unchanged | 1,892,200 | $168M |
| Mirum Pharmaceuticals Inc | 6.6% | Unchanged | 1,236,027 | $145M |
| KP Kiniksa Pharmaceuticals Intl | 6.6% | Unchanged | 2,259,889 | $145M |
| Celcuity Inc | 6.2% | Added 25% | 1,314,594 | $138M |
| Corcept Therapeutics Inc | 5.9% | Unchanged | 1,500,000 | $130M |
| Ptc Therapeutics Inc | 5.6% | Unchanged | 1,500,000 | $122M |
| Lakefront Biotherapeutics Nv | 5.2% | Unchanged | 3,785,991 | $114M |
| Capricor Therapeutics Inc | 4.5% | Added 21% | 4,099,900 | $98.7M |
| Tarsus Pharmaceuticals Inc | 4.5% | Added 32% | 1,568,266 | $98.7M |
| SS State Str SPDR S&P 500 ETF T | 4.2% | Trimmed 27% | 123,000 | $91.9M |
| Anaptysbio Inc | 4.1% | Unchanged | 1,330,879 | $89.8M |
| IH Immunocore Hldgs PLC | 3.8% | Unchanged | 2,649,368 | $84.1M |
| Compass Pathways PLC | 3.2% | Added 25% | 5,000,000 | $70.8M |
| Ani Pharmaceuticals Inc | 2.7% | Unchanged | 707,500 | $58.6M |
| Biontech Se | 2.0% | Unchanged | 470,000 | $43.7M |
| Compass Therapeutics Inc | 1.8% | Added 7.1% | 17,990,782 | $39.4M |
| Precigen Inc | 1.7% | Unchanged | 6,417,500 | $36.6M |
| VT Viridian Therapeutics Inc | 1.5% | Unchanged | 1,792,626 | $32.9M |
| Nuvectis Pharma Inc | 1.3% | New | 1,550,000 | $28.5M |
| DT Dianthus Therapeutics Inc | 1.2% | Unchanged | 264,692 | $25.8M |
| Fulcrum Therapeutics Inc | 1.1% | New | 6,521,412 | $23.9M |
| Atea Pharmaceuticals Inc | 1.0% | Unchanged | 4,814,700 | $22.4M |
| Crescent Biopharma Inc. | 0.9% | Unchanged | 1,160,000 | $20.9M |
| Nano Dimension Ltd | 0.9% | New | 14,292,813 | $20.7M |
| Viking Therapeutics Inc | 0.9% | Unchanged | 500,000 | $19.5M |
| Nuvation Bio Inc | 0.9% | Added 4.8% | 3,299,557 | $18.7M |
| Ideaya Biosciences Inc | 0.8% | Unchanged | 450,000 | $16.8M |
| Gossamer Bio Inc | 0.5% | New | 17,841,000 | $11.5M |
| JM Journey Med Corp | 0.5% | Unchanged | 1,610,000 | $11.4M |
| Insmed Inc | 0.5% | Trimmed 62% | 100,000 | $10.7M |
| Stoke Therapeutics Inc | 0.4% | Trimmed 40% | 300,000 | $9.82M |
| Pliant Therapeutics Inc | 0.3% | Trimmed 0.0% | 6,141,261 | $7M |
| Boundless Bio Inc | 0.3% | New | 2,559,875 | $6.4M |
| Pmv Pharmaceuticals Inc | 0.3% | Unchanged | 4,245,085 | $5.69M |
| Moderna Inc | 0.2% | Trimmed 50% | 50,000 | $3.5M |
| Wave Life Sciences Ltd | 0.2% | Unchanged | 600,000 | $3.49M |
| Heron Therapeutics Inc | 0.1% | Unchanged | 6,250,000 | $2.67M |
| Lenz Therapeutics Inc | 0.1% | Unchanged | 451,114 | $2.56M |
| Altimmune Inc | 0.1% | Unchanged | 666,022 | $2.02M |
| Rocket Pharmaceuticals Inc | 0.0% | Unchanged | 100,000 | $342K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Kalvista Pharmaceuticals Inc | Exited | −4,573,530 | −$92.1M | — |
| SS State Str SPDR S&P 500 ETF T | Trimmed | −45,000 | −$33.6M | 4.2% |
| Nuvectis Pharma Inc | New | +1,550,000 | +$28.5M | 1.3% |
| Celcuity Inc | Added | +264,594 | +$27.7M | 6.2% |
| Tarsus Pharmaceuticals Inc | Added | +379,642 | +$23.9M | 4.5% |
| Fulcrum Therapeutics Inc | New | +6,521,412 | +$23.9M | 1.1% |
| Nano Dimension Ltd | New | +14,292,813 | +$20.7M | 0.9% |
| Insmed Inc | Trimmed | −160,000 | −$17.1M | 0.5% |
| Capricor Therapeutics Inc | Added | +700,000 | +$16.9M | 4.5% |
| Compass Pathways PLC | Added | +997,800 | +$14.1M | 3.2% |
Showing the 10 largest of 32 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| SS State Str SPDR S&P 500 ETF T | Added | +138,000 | +$89.7M | 5.5% |
| Avidity Biosciences Inc | Exited | −900,000 | −$64.9M | — |
| Corcept Therapeutics Inc | Added | +1,343,236 | +$54.1M | 3.1% |
| Capricor Therapeutics Inc | Added | +1,699,900 | +$51.7M | 5.2% |
| Vertex Pharmaceuticals Inc | Exited | −80,000 | −$36.3M | — |
| Insmed Inc | Added | +200,000 | +$32.7M | 2.2% |
| Moderna Inc | Trimmed | −592,820 | −$30.1M | 0.3% |
| Travere Therapeutics Inc | Exited | −700,000 | −$26.7M | — |
| Ventyx Biosciences Inc | Exited | −2,814,000 | −$25.4M | — |
| Nvidia Corporation | Exited | −127,788 | −$23.8M | — |
Showing the 10 largest of 55 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Tarsus Pharmaceuticals Inc | Trimmed | −1,266,173 | −$104M | 4.8% |
| Avidity Biosciences Inc | New | +900,000 | +$64.9M | 3.2% |
| Merus N V | Exited | −600,000 | −$56.5M | — |
| Capricor Therapeutics Inc | New | +1,700,000 | +$49.1M | 2.4% |
| Spyre Therapeutics Inc | Trimmed | −1,307,800 | −$42.8M | 3.1% |
| Relay Therapeutics Inc | Exited | −8,068,058 | −$42.1M | — |
| VT Vera Therapeutics Inc Cl A | Exited | −1,350,000 | −$39.2M | — |
| Nike Inc | Exited | −519,399 | −$36.2M | — |
| Ionis Pharmaceuticals Inc | Exited | −550,000 | −$36M | — |
| Cytomx Therapeutics Inc | Exited | −11,065,662 | −$35.3M | — |
Showing the 10 largest of 187 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Celcuity Inc | New | +1,150,000 | +$56.8M | 2.2% |
| Precigen Inc | New | +12,400,000 | +$40.8M | 1.6% |
| Iteos Therapeutics Inc | Exited | −3,826,692 | −$38.2M | — |
| Nike Inc | Added | +500,000 | +$34.9M | 1.4% |
| Vertex Pharmaceuticals Inc | Added | +70,000 | +$27.4M | 1.2% |
| Ionis Pharmaceuticals Inc | Added | +400,000 | +$26.2M | 1.4% |
| Ptc Therapeutics Inc | Added | +400,000 | +$24.5M | 3.5% |
| Boeing Co | Trimmed | −102,437 | −$22.1M | — |
| Mettler-toledo International | Trimmed | −17,531 | −$21.5M | 0.1% |
| Aurinia Pharmaceuticals Inc | Added | +1,300,000 | +$14.4M | 4.8% |
Showing the 10 largest of 90 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Dynavax Technologies Corp | Trimmed | −3,800,500 | −$37.7M | 1.0% |
| IT Intra-cellular Therapies Inc | Exited | −220,000 | −$29M | — |
| VT Vera Therapeutics Inc Cl A | Added | +1,200,000 | +$28.3M | 1.6% |
| Merus N V | Added | +500,000 | +$26.3M | 1.6% |
| Acelyrin Inc | Exited | −9,818,115 | −$24.3M | — |
| Mettler-toledo International | New | +19,500 | +$22.9M | 1.2% |
| Boeing Co | Added | +99,594 | +$20.9M | 1.1% |
| Spyre Therapeutics Inc | Added | +1,150,000 | +$17.2M | 2.4% |
| Urogen Pharma Ltd | New | +1,000,000 | +$13.7M | 0.7% |
| Iteos Therapeutics Inc | Added | +1,137,492 | +$11.3M | 1.9% |
Showing the 10 largest of 126 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Dynavax Technologies Corp | Added | +3,900,000 | +$50.6M | 4.1% |
| GN Galapagos Nv | Added | +1,800,597 | +$45.2M | 5.5% |
| KP Kiniksa Pharmaceuticals Intl | Added | +1,489,970 | +$33.1M | 2.6% |
| Spyre Therapeutics Inc | New | +2,050,000 | +$33.1M | 1.8% |
| Acelyrin Inc | New | +9,818,115 | +$24.3M | 1.3% |
| Ptc Therapeutics Inc | Added | +300,000 | +$15.3M | 2.8% |
| Iteos Therapeutics Inc | Added | +2,467,484 | +$14.7M | 0.9% |
| Legend Biotech Corp | Added | +380,000 | +$12.9M | 1.6% |
| Aurinia Pharmaceuticals Inc | Added | +1,600,000 | +$12.9M | 4.5% |
| Keros Therapeutics Inc | New | +1,100,000 | +$11.2M | 0.6% |
Showing the 10 largest of 141 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| GN Galapagos Nv | Added | +1,461,200 | +$40.2M | 3.9% |
| Relay Therapeutics Inc | Added | +4,500,000 | +$18.5M | 2.2% |
| Replimune Group Inc | Added | +1,500,000 | +$18.2M | 2.2% |
| Iteos Therapeutics Inc | Trimmed | −2,186,084 | −$16.8M | 0.1% |
| Legend Biotech Corp | New | +450,000 | +$14.6M | 1.0% |
| IH Immunocore Hldgs PLC | Added | +450,000 | +$13.3M | 3.0% |
| RT Revance Therapeutics Inc | Exited | −2,500,000 | −$13M | — |
| Moderna Inc | New | +300,000 | +$12.5M | 0.8% |
| Aurinia Pharmaceuticals Inc | Added | +1,200,000 | +$10.8M | 5.0% |
| Immunome Inc | Exited | −720,000 | −$10.5M | — |
Showing the 10 largest of 134 changes.
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Aurinia Pharmaceuticals Inc | Added | +4,450,000 | +$32.6M | 3.8% |
| Biontech Se | New | +270,000 | +$32.1M | 2.3% |
| Relay Therapeutics Inc | New | +3,568,058 | +$25.3M | 1.8% |
| Iteos Therapeutics Inc | New | +2,407,800 | +$24.6M | 1.8% |
| Eli Lilly & Co | Exited | −27,000 | −$24.4M | — |
| IH Immunocore Hldgs PLC | Added | +700,000 | +$21.8M | 2.5% |
| VT Viridian Therapeutics Inc | Added | +850,000 | +$19.3M | 3.6% |
| GN Galapagos Nv | Added | +644,391 | +$18.6M | 1.4% |
| Neurocrine Biosciences Inc | New | +150,000 | +$17.3M | 1.2% |
| Novavax Inc | New | +1,000,000 | +$12.6M | 0.9% |
Showing the 10 largest of 101 changes.
Loading...
